Table 5.
Baseline clinical data and treatment outcomes of patients with 1-month radiological complete response
| Variable | Lipiodol-TACE, n = 53 | DEB-TACE, n = 52 | p | |
|---|---|---|---|---|
| Age (years) | Mean ± sd | 63.7 ± 10.1 | 63.3 ± 10.2 | 0.84 |
| Range | 38–85 | 46–85 | ||
| Gender (male) | Male/female | 40/13 | 44/8 | 0.24 |
| Cause of cirrhosis | Absent | 1 (1.9) | 2 (3.8) | 0.63 |
| HCV | 32 (60.4) | 36 (69.2) | ||
| HBV | 8 (15.1) | 7 (13.5) | ||
| Alcohol | 8 (15.1) | 3 (5.8) | ||
| Dysmetabolic | 2 (3.8) | 3 (5.8) | ||
| Other* | 2 (3.8) | 1 (1.9) | ||
| Child-Pugh | A | 49 (92.4) | 44 (84.6) | 0.39 |
| B | 3 (5.7) | 7 (13.5) | ||
| Not applicable | 1 (1.9) | 1 (1.9) | ||
| BCLC stage | 0 | 5 (9.4) | 4 (7.7) | 0.98 |
| A | 35 (66) | 36 (69.2) | ||
| B | 12 (22.6) | 11 (21.2) | ||
| C | 1 (1.9) | 1 (1.9) | ||
| Tumor extension | Unifocal | 30 (56.6) | 32 (61.5) | 0.61 |
| Unilobar | 44 (83) | 43 (82.7) | 0.96 | |
| Diameter of largest lesion (mm) | Mean ± sd | 32.3 ± 17.7 | 32.6 ± 12.8 | 0.91 |
| Range | 15–110 | 10–67 | ||
| < 30 | 27 (50.9) | 21 (40.4) | ||
| 30-49 | 18 (34) | 24 (46.1) | ||
| 50-70 | 6 (11.3) | 7 (13.5) | ||
| > 70 | 2 (3.8) | 0 (0) | ||
| Dose of doxorubicin (mg) | Mean ± sd | 55.4 ± 14.5 | 65.1 ± 22.2 | 0.009 |
| Range | 12–75 | 30–150 | ||
| Follow-up duration (months) | Median | 30.6 | 37.5 | 0.88 |
| Range | 3.4–123.1 | 6.1–99.6 | ||
| Time to target tumor progression (months) | Median | 11.8 | 27.8 | 0.009 |
| 95%CI | 9.5–15.8 | 12.6–NR | ||
| Time to tumor progression (months) | Median | 12.2 | 19.7 | 0.099 |
| 95%CI | 9.4–21.2 | 13.9–30.2 | ||
| Time to extrahepatic progression (months) | Median | 55.1 | N.R. | 0.37 |
| 95%CI | 38.2–N.R. | 29.4–N.R. | ||
| N. of treatments post-TACE | Mean ± sd | 1.60 ± 2.2 | 0.75 ± 1.20 | 0.016 |
| Post-TACE Liver transplantation (yes) | 6 (11.3) | 14 (26.9) | 0.04 | |
| Overall survival (months) | Median | 29.2 | 35.1 | 0.49 |
| 95%CI | 27.8–44.2 | 28-53.3 |
*Other: cryptogenetic (n = 3)
When not otherwise specified, data are given as numbers (and percentages)
NR, not reached